A new international study has delivered a rare dose of good news in the fight against aggressive brain tumors. Researchers found that a drug combination helped adults with recurrent grade 3 ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the U.S. Food and Drug ...
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback